VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
VERAXA Biotech AG and Secarna Pharmaceuticals announced promising initial results from their collaboration developing antibody oligonucleotide conjugates (AOCs), showing enhanced potency in early in vitro studies. This milestone underscores the therapeutic potential of AOCs to improve targeted treatments for autoimmune and chronic immune diseases. …